(Reuters) – Emergent BioSolutions Inc signed a five-year agreement with Providence Therapeutics to develop and manufacture its COVID-19 vaccine candidate, the companies said on Tuesday.
The agreement signed between Emergent and Providence Therapeutics is valued at about $90 million.
(Reporting by Mrinalika Roy in Bengaluru; Editing by Shinjini Ganguli)
